“The AIPAC-003 trial consists of an open-label dose optimization lead-in component ”
The ongoing randomized Phase II portion of the trial, which will include up to 58 evaluable patients, is focused on whether 90mg efti dosing is safe and more efficacious than 30mg dosing. This portion of the trial has enrolled 23 patients to date.
Could we get an update at ESMO ,on ,patients progress in the next couple of days?
“The AIPAC-003 trial consists of an open-label dose optimization...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.3¢ |
Change
-0.008(1.70%) |
Mkt cap ! $523.0M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 44.0¢ | 43.3¢ | $104.6K | 239.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 186786 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.5¢ | 28076 | 6 |
View Market Depth
| Last trade - 10.13am 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
43.5¢ |
Change
-0.008 ( 1.23 %) |
||||
| Open | High | Low | Volume | ||
| 43.5¢ | 43.5¢ | 43.0¢ | 69500 | ||
| Last updated 10.19am 30/05/2024 ? | |||||
| IMM (ASX) Chart |